國家衛生研究院 NHRI:Item 3990099045/2938
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12189/12972 (94%)
造訪人次 : 955539      線上人數 : 754
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/2938


    題名: Phase I and pharmacokinetic study of oral thalidomide in patients with advanced hepatocellular carcinoma
    作者: Shiah, HS;Chao, Y;Chen, LT;Yao, TJ;Huang, JD;Chang, JY;Chen, PJ;Chuang, TR;Chin, YH;Whang-Peng, J;Liu, TW
    貢獻者: National Institute of Cancer Research;Division of Biostatistics and Bioinformatics;Division of Biotechnology and Pharmaceutical Research
    摘要: Purpose: To evaluate the dose-limiting toxicities (DLT), maximum tolerated dose (MTD), and pharmacokinetics of thalidomide in patients with advanced hepatocellular carcinoma (HCC). Methods: Patients with advanced HCC who were not feasible for definitive local therapy were eligible. Patients were enrolled in a cohort of three to receive thalidomide twice daily for 1 week to determine the MTD. Intra-patient dose escalation was permitted. Pharmacokinetic studies were performed at the first dose level and repeated at the second dose level of each patient. Results: Fifteen patients were accrued at four dose levels with the starting dose range 100-400 mg/day. Two patients at 400 mg/day experienced DLT (grade 3 angioedema and dyspnea, respectively). The MTD of twice-daily schedule was determined as 300 mg/day. The mean steady-state maximal blood concentration and mean steady-state area under the curve had a trend toward positive correlation, but non-linear proportionate, to the daily dose of thalidomide. Pharmacokinetic parameters are comparable for patients of Child-Pugh's A and B. Apparent mild, transient drug-induced transaminitis was early onset, self-limited, which occurred in 30.7% of patients. Serum hepatitis B or C viral titers was largely not affected. Conclusion: The absorption and elimination of thalidomide are not significantly different in HCC patients with compensated or decompensated hepatic dysfunction.
    關鍵詞: Oncology;Pharmacology & Pharmacy
    日期: 2006-11
    關聯: Cancer Chemotherapy and Pharmacology. 2006 Nov;58(5):654-664.
    Link to: http://dx.doi.org/10.1007/s00280-006-0203-z
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0344-5704&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000239485000012
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84984535366
    顯示於類別:[劉滄梧] 期刊論文
    [夏和雄(1996-2012)] 期刊論文
    [張俊彥] 期刊論文
    [彭汪嘉康(1996-2007)] 期刊論文
    [陳立宗] 期刊論文
    [其他] 期刊論文
    [姚姿君(1999-2002)] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    000239485000012.pdf283KbAdobe PDF957檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋